CJC-1295 (no DAC) 5mg / Ipamorelin 5mg (blend)

CJC-1295 (No DAC) / Ipamorelin Blend – Dual Growth Hormone Secretagogue Research Compound

Overview

Researchers often turn to the CJC-1295 (no DAC) / Ipamorelin blend as a go-to combination for GH axis studies. By pairing a GHRH analogue with a selective GHRP (growth hormone releasing peptide) in one preparation, it targets two different but complementary receptors within the pituitary-hypothalamic axis. The logic’s simple: since GHRH and GHRP compounds trigger GH release via separate receptor pathways, putting them together creates a much stronger GH pulse than you’d see with either one on its own.

CJC-1295 without DAC (Drug Affinity Complex) is a modified analogue of growth hormone-releasing hormone (GHRH). It keeps the same receptor binding but lacks the albumin-binding modification found in the DAC version. This results in a shorter half-life that closely mimics the natural GHRH pulsatile pattern, making it a better fit for researchers studying pulsatile GH secretion rather than prolonged elevation. Ipamorelin is a synthetic pentapeptide acting as a selective ghrelin receptor agonist. It triggers GH release from pituitary somatotrophs while maintaining a clean hormonal profile. It doesn’t significantly raise cortisol or prolactin at research-relevant doses, which distinguishes it from earlier GHRPs like GHRP-6.

We’ve put 5mg of CJC-1295 (no DAC) and 5mg of Ipamorelin into every vial of this blend. If you’re conducting studies that require these as individual compounds, CJC-1295 W/O DAC 2mg and Ipamorelin 2mg are also available separately. For research purposes only.

Research Applications

Researchers mostly use this blend to study growth hormone secretion dynamics, GH axis modulation, and downstream IGF-1 signalling. It’s also a useful tool for metabolic research, body composition studies, and looking into age-related GH decline.

• GH pulse amplitude and frequency modelling — studying pulsatile versus sustained GH release patterns
• IGF-1 signalling pathways — downstream effects of GH axis activation on hepatic and peripheral IGF-1 production
• Metabolic research — effects of GH axis stimulation on lipolysis, protein synthesis, and glucose metabolism
• Body composition studies in animal models — lean mass accretion versus fat oxidation
• Somatotroph biology — receptor-level studies on GHRH-R and ghrelin receptor co-activation
• Comparison studies against longer-acting GH secretagogues like CJC-1295 W/ DAC 2mg

If researchers are building broader GH axis panels, they might include GHRP-2 5mg or Sermorelin 2mg for receptor-binding comparison studies. The investigator could also use IGF-1 LR3 1mg for downstream signalling investigations.

Molecular Profile

CJC-1295 (no DAC) is a 30-amino acid GHRH analogue with the sequence Ser-Tyr-Ser-Arg-Ile-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-Gln-Gln-Gly-Glu-Ser-Asn-Gln-Glu-Arg-Gly-Ala-Arg-Ala-Arg-Leu. It has a molecular weight of approximately 3,367 g/mol and is identified by CAS number 863288-34-0. This peptide is intended for research purposes only and isn’t for human administration. It should only be handled by qualified investigators in a laboratory setting.

Ipamorelin’s sequence is Aib-His-D-2Nal-D-Phe-Lys-NH₂. It’s got a C₃₈H₄₉N₉O₅ molecular formula, a 711.87 g/mol MW, and CAS 170851-70-4.

Purity for both is ≥98% by HPLC. The lyophilised vial contains 5mg CJC-1295 (no DAC) and 5mg Ipamorelin.

Mechanism of Action

CJC-1295 (no DAC) works by binding to the GHRH receptor (GHRH-R) on pituitary somatotrophs. This process kicks off a classic G-protein coupled receptor signalling cascade, activating adenylate cyclase and boosting intracellular cAMP, which eventually triggers GH synthesis and secretion. Since this no-DAC version doesn’t have the maleimidopropionic acid modification needed for albumin binding, it acts a lot like natural GHRH. It functions in a pulsatile way instead of causing the long, sustained GH elevation seen with other variants. This product is for research purposes only and is not intended for human administration; it should only be handled by qualified investigators.

Ipamorelin works through a completely different pathway by targeting the ghrelin receptor (GHS-R1a). It activates phospholipase C and the IP₃/DAG pathway, which triggers the release of intracellular calcium and leads to GH exocytosis. What makes it stand out is its high level of selectivity; it shows minimal stimulation of ACTH, cortisol, or prolactin, even at doses that cause substantial GH release. This precision is why researchers often prefer ipamorelin over older GHRPs like GHRP-6 or Hexarelin.

When paired together, GHRH analogues and ghrelin receptor agonists synergise at the pituitary level, triggering GH pulses significantly larger than what either achieves on its own. Rodent studies have documented this synergy, and it’s the mechanistic rationale that drove early combination human trials. This makes the blend a particularly useful tool for researchers investigating the cooperative regulation of GH secretion.

Storage and Handling

Store the lyophilised blend at −20°C, ensuring it is kept away from light and moisture. Reconstitute with bacteriostatic water only when the researcher is ready for application. Once reconstituted, the solution remains stable at 2–8°C for up to 4 weeks. The investigator should avoid repeated freeze-thaw cycles. Handle under standard aseptic laboratory conditions. For research use only.

References

• Raun K, et al. “Ipamorelin, the first selective growth hormone secretagogue.” European Journal of Endocrinology. 1998;139(5):552–561.
• Teichman SL, et al. “Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults.” Journal of Clinical Endocrinology & Metabolism. 2006;91(3):799–805.
• Bowers CY. “Growth hormone-releasing peptide (GHRP).” Cell and Molecular Life Sciences. 1998;54(12):1316–1329.
• Popovic V, et al. “Synergistic effect of GHRH and GHRP-6 on GH secretion.” Journal of Clinical Endocrinology & Metabolism. 1995;80(11):3268–3272.
• Veldhuis JD, et al. “Somatotropic axis coupling to the rhythmic pattern of GH secretion.” Endocrine Reviews. 2003;24(3):327–355.